Who we are

CardioVax is a Los Angeles based biotechnology company focusing on immunotherapies for cardiovascular disease. The company has evolved from innovative discoveries at the Lund University Hospital in Malmö and Cedars-Sinai Medical Center.

What we do

We are developing immune therapies to treat cardiovascular disease, the number one cause of death globally. CardioVax therapies build protection against the accumulation of plaque within the walls of blood vessels which is responsible for most heart attacks and strokes.

Our products

Our products in preclinical development include an injectable vaccine, a mucosal vaccine, and an autologous cellular immunotherapy (a treatment using the patient's own cells). Each of these technologies is being optimized in the laboratory so that they will be safe for human trials.

Dr. Jan Nilsson

Founder, scientific advisor

Stacey Ruiz, Ph.D.

VP, DRUG DEVELOPMENT & DISCOVERY

Dr. Prediman K. Shah

Founder, scientific advisor

John Farina

CHAIRMAN

Chris Farina

VP, Operations
CV Logo Footer

10100 Santa Monica Blvd., Suite 925

Los Angeles, CA 90067 United States

Tel.: 424. 263. 6364